University of East Anglia Research Opportunity

by P. Brady | Feb 17, 2021 | Medication, News, Research

The relationship between feelings of control, low mood, and medication adherence in people with Parkinson’s Dr Nick Zarotti, a trainee clinical psychologist at the University of East Anglia, is looking at how feeling in control could be linked to low mood and...

January/February 2021 Research Roundup

by P. Brady | Feb 17, 2021 | News, Research

Our Research Support Network (RSN) connects you to Parkinson’s research. From finding out more about research to getting involved, there’s something for everyone. You can register to receive our research emails directly by visiting...

New Research into Dyskinesia Drug announced

by P. Brady | Nov 30, 2020 | Future Treatment, News, Research

Parkinson’s UK is joining forces with US Charity The Michael J. Fox Foundation and biopharma company Neurolixis to fund a £1.5 m clinical trial of an exciting new drug to combat Dyskinesia in people with Parkinson’s. FIND OUT MORE Featured image by Michael Longmire on...

Federal ban for paraquat in US?

by Jim Bolt | Aug 18, 2020 | News, Research

An email from the Michael J Fox Foundation tells us that the US Congress is about to discuss legislation to ban the highly toxic weedkiller paraquat. Scientists have cited the deadly herbicide as a causal factor in many cases of Parkinson’s, either from direct contact...

Light therapies and Parkinson’s

by Jim Bolt | Aug 18, 2020 | Research, Therapies

As an infra red lamp user, I was interested to read Katherine Fletcher’s blog post about the therapeutic uses of light on the Parkinson’s UK website. The data are limited, but Katherine thought some lines of inquiry look promising. She poses the question of how light...

France gives green light for CBD evaluation

by Jim Bolt | Aug 18, 2020 | Future Treatment, Medication, News, Research

The French parliament has authorised a two-year legalisation of medicinal cannabis to allow scientists time to evaluate the medicinal properties of cannabidiol (CBD) for a number of conditions, including Parkinson’s and Multiple Sclerosis. In July this year, the...